Q1 2023

Filed May 11, 2023 · 10-Q · 41 days after period end · 0001615219-23-000038

Q1 2023 · 10-Q

Revenue

$0.00

— vs Q1 2022

Net Income

-$5.34M

N/M vs Q1 2022

EPS Diluted

-$2.23

N/M vs Q1 2022

Operating Income-$5,420,663N/M

Operating Cash Flow

Same quarter

Metric	Q1 2023	Q1 2022	Q1 2021	Q1 2020
Revenue	$0.00	$0.00	$1.27M	$1.13M
Net Income	-$5.34M	-$6.11M	-$1.85M	-$2.08M
EPS Diluted	-$2.23	-$3.30	-$0.06	-$0.22

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR